Tickers visitors are watching

One reason these four names kept popping up is that they sit in very different corners of the market, but each one had a fresh hook in April: CoreWeave got a huge capacity deal, Palantir kept feeding the artificial intelligence software story, Marvell stayed tied to custom chip infrastructure, and Galmed had new filing activity that put a tiny biotech back on screens. (coreweave.com) (investors.palantir.com) (investor.marvell.com) (galmedpharma.investorroom.com) CoreWeave is the clearest example of why traders suddenly treated a stock like a theme instead of a ticker. On April 9, 2026, CoreWeave said Meta would buy about $21 billion of artificial intelligence cloud capacity through December 2032, spread across multiple sites and including some early NVIDIA Vera Rubin deployments. (coreweave.com) That turns CoreWeave into something closer to a landlord for artificial intelligence computing than a normal software company. Meta is not buying an app here; it is reserving power, servers, and networked machine capacity the way an airline reserves gates at an airport years in advance. (coreweave.com) Palantir sits on the other side of the same trade. Its pitch is software that helps governments and companies turn messy data into decisions, and on February 2, 2026, it reported fourth-quarter revenue of $1.407 billion, up 70% from a year earlier, with United States commercial revenue up 137% to $507 million. (investors.palantir.com) Palantir also kept the story alive in March with its ninth Artificial Intelligence Platform Conference, where it put customers like the United States Navy, GE Aerospace, SAP, Accenture, and healthcare groups on stage to show live use cases. That kind of event gives traders a steady stream of names, contracts, and demos to point to when the stock becomes a proxy for “enterprise artificial intelligence is still spending.” (palantir.com 1) (palantir.com 2) Marvell is the hardware middleman in this group. Its investor page says the company powers artificial intelligence, cloud, carrier, and enterprise infrastructure, and on March 31, 2026, it highlighted a new link-up with NVIDIA around NVLink Fusion, which is NVIDIA’s system for tying custom chips into the same high-speed fabric used in large artificial intelligence racks. (investor.marvell.com) That is why Marvell gets mentioned when money rotates into “picks and shovels” names. If CoreWeave is renting out the factory floor and Palantir is selling the operating system, Marvell is helping build the wiring, connectivity, and custom silicon that let the whole factory run at scale. (investor.marvell.com) Galmed is the outlier because it is not part of the big artificial intelligence buildout at all. What put it back into trader chatter was corporate filing activity: Galmed posted an annual report on March 31, 2026, and an effectiveness notice on April 1, 2026, which is the kind of paperwork that can pull a thinly traded biotech into short-term speculation even before there is a major drug headline. (galmedpharma.investorroom.com) Put together, the list says less about one sector than about the kind of market traders were playing this week. CoreWeave and Marvell were infrastructure bets, Palantir was an application-layer artificial intelligence bet, and Galmed was a small-cap biotech setup where filings and float can matter as much as fundamentals in the short run. (coreweave.com) (investor.marvell.com) (investors.palantir.com) (galmedpharma.investorroom.com) That is why these names travel together even though their businesses do not. In a tactical market, traders often group stocks by what they can become over the next few sessions: a giant contract, a visible growth print, a critical hardware role, or a tiny biotech catalyst with fresh filings on the tape. (coreweave.com) (investors.palantir.com) (investor.marvell.com) (galmedpharma.investorroom.com)